NextCure, Inc.

NasdaqGS:NXTC Stock Report

Market Cap: US$27.2m

NextCure Management

Management criteria checks 3/4

NextCure's CEO is Michael Richman, appointed in Oct 2015, has a tenure of 9.17 years. total yearly compensation is $1.04M, comprised of 54.7% salary and 45.3% bonuses, including company stock and options. directly owns 1.45% of the company’s shares, worth $394.13K. The average tenure of the management team and the board of directors is 5.2 years and 4.3 years respectively.

Key information

Michael Richman

Chief executive officer

US$1.0m

Total compensation

CEO salary percentage54.7%
CEO tenure9.2yrs
CEO ownership1.5%
Management average tenure5.2yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

Here's Why We're Watching NextCure's (NASDAQ:NXTC) Cash Burn Situation

Nov 13
Here's Why We're Watching NextCure's (NASDAQ:NXTC) Cash Burn Situation

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Jul 17
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Mar 23
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Dec 09
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?

Aug 23
Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?

Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?

May 10
Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Nov 22
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Estimating The Intrinsic Value Of NextCure, Inc. (NASDAQ:NXTC)

Aug 09
Estimating The Intrinsic Value Of NextCure, Inc. (NASDAQ:NXTC)

NextCure GAAP EPS of -$0.59

Aug 04

We're Not Very Worried About NextCure's (NASDAQ:NXTC) Cash Burn Rate

May 02
We're Not Very Worried About NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure: Large Upside With Downside Protected By Cash Pile

Sep 29

NextCure (NXTC) Presents at 7th Annual Truist Securities Life Sciences Summit - Slideshow

May 10

NextCure EPS misses by $0.01

May 06

Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like

Feb 12
Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like

NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares

Jan 08
NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares

NextCure provides update on NC318 clinical program

Dec 17

CEO Compensation Analysis

How has Michael Richman's remuneration changed compared to NextCure's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$59m

Jun 30 2024n/an/a

-US$61m

Mar 31 2024n/an/a

-US$64m

Dec 31 2023US$1mUS$572k

-US$63m

Sep 30 2023n/an/a

-US$66m

Jun 30 2023n/an/a

-US$70m

Mar 31 2023n/an/a

-US$70m

Dec 31 2022US$2mUS$549k

-US$75m

Sep 30 2022n/an/a

-US$74m

Jun 30 2022n/an/a

-US$73m

Mar 31 2022n/an/a

-US$73m

Dec 31 2021US$3mUS$529k

-US$69m

Sep 30 2021n/an/a

-US$68m

Jun 30 2021n/an/a

-US$66m

Mar 31 2021n/an/a

-US$63m

Dec 31 2020US$6mUS$491k

-US$37m

Sep 30 2020n/an/a

-US$32m

Jun 30 2020n/an/a

-US$24m

Mar 31 2020n/an/a

-US$18m

Dec 31 2019US$626kUS$419k

-US$34m

Sep 30 2019n/an/a

-US$30m

Jun 30 2019n/an/a

-US$27m

Mar 31 2019n/an/a

-US$24m

Dec 31 2018US$3mUS$383k

-US$23m

Compensation vs Market: Michael's total compensation ($USD1.04M) is above average for companies of similar size in the US market ($USD654.40K).

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.

CEO

Michael Richman (63 yo)

9.2yrs

Tenure

US$1,044,627

Compensation

Mr. Michael S. Richman, MSBA, Co-founded NextCure, Inc. since 2015 and has been its Chief Executive Officer, President & Director since July 2015. Mr. Richman served as the Chief Executive Officer and Pres...

Leadership Team

NamePositionTenureCompensationOwnership
Michael Richman
Co-Founder9.2yrsUS$1.04m1.45%
$ 394.1k
Solomon Langermann
Chief Scientific Officer6yrsUS$681.59k0.13%
$ 36.2k
Lieping Chen
Co-Founder & Chairman of Scientific Advisory Board9.9yrsno datano data
Steven Cobourn
Chief Financial Officer6.9yrsUS$1.01mno data
Timothy Mayer
Chief Operating Officer5.2yrsno datano data
Kevin Shaw
Senior VP & General Counsel2.6yrsno datano data
Sourav Kundu
Senior Vice President of Development & Manufacturing3.4yrsno datano data
Sebastien Maloveste
Senior Vice President of Business Development1.4yrsno datano data
Udayan Guha
Senior Vice President of Clinical & Translational Development1.3yrsno datano data

5.2yrs

Average Tenure

63yo

Average Age

Experienced Management: NXTC's management team is seasoned and experienced (5.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Michael Richman
Co-Founder9.2yrsUS$1.04m1.45%
$ 394.1k
Lieping Chen
Co-Founder & Chairman of Scientific Advisory Boardno datano datano data
Elaine Jones
Independent Director9yrsUS$67.47k0%
$ 0
Mario Sznol
Member of Scientific Advisory Boardno datano datano data
David Kabakoff
Independent Chairman of the Board9yrsUS$93.16k0.22%
$ 60.4k
Stephen Webster
Independent Director5.7yrsUS$71.66k0%
$ 0
Ellen Feigal
Independent Director3.2yrsUS$61.66k0%
$ 0
Stephen Miller
Member of Scientific Advisory Boardno datano datano data
John Houston
Independent Director4.3yrsUS$61.66k0%
$ 0
Weiping Zou
Member of Scientific Advisory Board3.2yrsno datano data
Ursula Matulonis
Member of Scientific Advisory Board3.2yrsno datano data
Anne Borgman-Hagey
Independent Director3.2yrsUS$60.66k0%
$ 0

4.3yrs

Average Tenure

66yo

Average Age

Experienced Board: NXTC's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 01:44
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NextCure, Inc. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aydin HuseynovBenchmark Company
Alec StranahanBofA Global Research
null nullBTIG